Please login to the form below

Not currently logged in
Email:
Password:

DBV Technologies

This page shows the latest DBV Technologies news and features for those working in and with pharma, biotech and healthcare.

EU authorises Aimmune’s peanut allergy treatment Palforzia

EU authorises Aimmune’s peanut allergy treatment Palforzia

Aimmune’s potential rival, DBV Technologies, has not had as much success with getting its peanut allergy treatment approved. ... In August, DBV announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA

Latest news

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... The setback means that DBV’s drug loses further ground

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    California biotech Aimmune has been in a race to market with rival companies like France’s DBV Technologies, which filed for approval of its Viaskin Peanut skin patch-based product at ... DBV’s share price in the last few weeks.

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    of rivals including DBV Technologies which has a patch-based immunotherapy product in late-stage development. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... DBV says its new filing “incorporates additional data needs on

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the marketing application for its Viaskin Peanut patch ... DBV has said it intends to refile with the US agency

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics